LSV Asset Management Purchases 99,705 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

LSV Asset Management grew its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 4.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,480,563 shares of the specialty pharmaceutical company's stock after buying an additional 99,705 shares during the quarter. LSV Asset Management owned about 3.93% of Jazz Pharmaceuticals worth $264,750,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JAZZ. Foundry Partners LLC bought a new position in shares of Jazz Pharmaceuticals during the second quarter valued at approximately $323,000. Arizona State Retirement System lifted its position in shares of Jazz Pharmaceuticals by 0.8% during the 2nd quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company's stock valued at $1,770,000 after acquiring an additional 130 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of Jazz Pharmaceuticals by 42.7% during the 2nd quarter. Victory Capital Management Inc. now owns 205,492 shares of the specialty pharmaceutical company's stock valued at $21,932,000 after acquiring an additional 61,458 shares during the last quarter. Natixis Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 10.7% during the 2nd quarter. Natixis Advisors LLC now owns 21,231 shares of the specialty pharmaceutical company's stock valued at $2,266,000 after acquiring an additional 2,054 shares during the last quarter. Finally, Waterfront Wealth Inc. boosted its position in Jazz Pharmaceuticals by 2.5% during the 2nd quarter. Waterfront Wealth Inc. now owns 9,411 shares of the specialty pharmaceutical company's stock worth $1,004,000 after acquiring an additional 230 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have commented on JAZZ. Wells Fargo & Company decreased their price objective on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an "equal weight" rating on the stock in a report on Thursday, August 1st. Robert W. Baird reduced their price objective on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an "outperform" rating on the stock in a research note on Thursday, August 1st. Needham & Company LLC dropped their target price on shares of Jazz Pharmaceuticals from $208.00 to $205.00 and set a "buy" rating on the stock in a report on Thursday, August 1st. Royal Bank of Canada dropped their target price on shares of Jazz Pharmaceuticals from $175.00 to $174.00 and set an "outperform" rating on the stock in a report on Thursday, August 1st. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an "overweight" rating in a report on Monday, August 19th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $173.07.

Jazz Pharmaceuticals Stock Down 1.2 %

Jazz Pharmaceuticals stock traded down $1.25 during mid-day trading on Friday, hitting $107.14. The company had a trading volume of 1,160,096 shares, compared to its average volume of 692,521. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. The stock's 50 day moving average price is $109.75 and its two-hundred day moving average price is $112.12. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $137.57. The company has a market capitalization of $6.76 billion, a PE ratio of 22.09, a price-to-earnings-growth ratio of 1.45 and a beta of 0.57.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.